EMA sees fee income reduced by €8m
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is facing a €8m drop in estimated revenue from industry fees this year as a result of changes to the parameters used to calculate fee income. At the same time, it is facing a constantly growing workload including a rise in the number of initial drug approval applications this year, driven mainly by an increase in orphan drug filings.